Role of Human Kallikrein 6 as a Serum Biomarker in Early Diagnosis of Ovarian Carcinoma

Document Type : Original Article

Authors

1 Obstetrics and Gynecology department,Benha facuty of medicine, Benha university

2 Obstetrics and gynecology department, faculty of medicine, Zagazig university

3 Obstetric and gynecology department faculty of medicine Zagazig university

4 Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University

Abstract

Objective : Serum levels of hk6 for patients with benign ovarian masses, malignant ovarian masses, and normal healthy controls are to be measured and compared.
Methods : Two groups of women were included in the study : Group 1:ninety-nine women who had ovarian swellings that required laparotomy or laparoscopic surgery after being detected clinically and radiologically Group 2:Seven women who appeared to be in good health served as controls (women attending to Gynecological outpatient clinic for family planning consultation from).
Results : Groups with benign neoplasms and those with malignant ovarian masses had greater blood levels of hk6, with the former group having a higherlevel than the latter. A CA125 level of 31.51 or above yielded 73% sensitivity, 80% specificity, and 59% positive predictive value; an 88% negative predictive value was the optimal cut off point. Each biomarker's diagnostic sensitivity and accuracy have risen when ca125 and hk6 are combined.
Conclusion: Serum hk6 concentration is an easy-to-use and dependable immunoassay for ovarian cancer patient management. When it comes to ovarian cancer diagnostic confirmation, CA-125 remains the gold standard for confirmation of diagnosis ofovarian cancer. CA125 is clinically approved for following the response to treatment and predicting prognosis after treatment but the addition of hk6 may increase sensitivity and this should be taken into consideration.

Keywords

Main Subjects

Files

Share

How to cite

Statistics